Farzaneh Aavani, Roja Rahimi, Pouya Goleij, Hossein Rezaeizadeh, Roodabeh Bahramsoltani
{"title":"Royal jelly and its hormonal effects in breast cancer: a literature review.","authors":"Farzaneh Aavani, Roja Rahimi, Pouya Goleij, Hossein Rezaeizadeh, Roodabeh Bahramsoltani","doi":"10.1007/s40199-024-00513-2","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Breast cancer is the most common cancer in women which can be cured in most individuals with early-stage non-metastatic disease. Imbalance in estrogen signaling pathways and propagating levels of estrogens has important roles in breast cancer development. Targeting the estrogen receptor signaling pathway is linked to breast cancer treatment. Royal jelly is one of the bee products containing 10-hydroxy-2-decenoic acid, a structure similar to mammalian estrogen, allowing it to attach to estrogen receptors. It is considered as a general tonic and immunomodulator which may be helpful in reducing the side effects of cancer treatments. Currently, there are controversial data regarding the pros and cons of royal jelly in cancer. Here we provide an overview of the effects of royal jelly on sex hormones and its possible role in breast cancer.</p><p><strong>Methods: </strong>Electronic databases including PubMed, Scopus, and Web of Science were searched with the search terms royal jelly, cancer, and sexual hormones. All preclinical and clinical studies regarding the hormonal effects of royal jelly were included.</p><p><strong>Results: </strong>According to the collected preclinical data, consumption of royal jelly at daily doses below 200 mg/kg can be useful to decrease the risk of breast cancer since it reduces the serum level of estrogen; whereas increases progesterone, which subsequently decreases the expression of ERs on the ER-positive cells.</p><p><strong>Conclusion: </strong>Future clinical studies are essential to confirm the safe dose of royal jelly as an adjuvant therapy in breast cancer.</p>","PeriodicalId":10888,"journal":{"name":"DARU Journal of Pharmaceutical Sciences","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"DARU Journal of Pharmaceutical Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40199-024-00513-2","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/8 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Breast cancer is the most common cancer in women which can be cured in most individuals with early-stage non-metastatic disease. Imbalance in estrogen signaling pathways and propagating levels of estrogens has important roles in breast cancer development. Targeting the estrogen receptor signaling pathway is linked to breast cancer treatment. Royal jelly is one of the bee products containing 10-hydroxy-2-decenoic acid, a structure similar to mammalian estrogen, allowing it to attach to estrogen receptors. It is considered as a general tonic and immunomodulator which may be helpful in reducing the side effects of cancer treatments. Currently, there are controversial data regarding the pros and cons of royal jelly in cancer. Here we provide an overview of the effects of royal jelly on sex hormones and its possible role in breast cancer.
Methods: Electronic databases including PubMed, Scopus, and Web of Science were searched with the search terms royal jelly, cancer, and sexual hormones. All preclinical and clinical studies regarding the hormonal effects of royal jelly were included.
Results: According to the collected preclinical data, consumption of royal jelly at daily doses below 200 mg/kg can be useful to decrease the risk of breast cancer since it reduces the serum level of estrogen; whereas increases progesterone, which subsequently decreases the expression of ERs on the ER-positive cells.
Conclusion: Future clinical studies are essential to confirm the safe dose of royal jelly as an adjuvant therapy in breast cancer.
背景：乳腺癌是女性最常见的癌症，大多数早期非转移性乳腺癌患者可以治愈。雌激素信号通路的失衡和雌激素水平的升高在乳腺癌的发展中起着重要作用。针对雌激素受体信号通路的治疗与乳腺癌的治疗有关。蜂王浆是蜂产品之一，含有10-羟基-2-癸烯酸，其结构与哺乳动物的雌激素相似，可附着在雌激素受体上。蜂王浆被认为是一种综合滋补品和免疫调节剂，可能有助于减轻癌症治疗的副作用。目前，关于蜂王浆对癌症的利弊还存在争议。在此，我们概述了蜂王浆对性激素的影响及其在乳腺癌中可能发挥的作用：方法：以蜂王浆、癌症和性激素为检索词，对PubMed、Scopus和Web of Science等电子数据库进行检索。所有有关蜂王浆荷尔蒙作用的临床前和临床研究均被纳入：结果：根据收集到的临床前数据，每天食用低于200毫克/千克剂量的蜂王浆可降低罹患乳腺癌的风险，因为蜂王浆可降低血清中的雌激素水平，同时增加孕酮，从而减少ER阳性细胞中ERs的表达：未来的临床研究对于确定蜂王浆作为乳腺癌辅助疗法的安全剂量至关重要。
期刊介绍：
DARU Journal of Pharmaceutical Sciences is a peer-reviewed journal published on behalf of Tehran University of Medical Sciences. The journal encompasses all fields of the pharmaceutical sciences and presents timely research on all areas of drug conception, design, manufacture, classification and assessment.
The term DARU is derived from the Persian name meaning drug or medicine. This journal is a unique platform to improve the knowledge of researchers and scientists by publishing novel articles including basic and clinical investigations from members of the global scientific community in the forms of original articles, systematic or narrative reviews, meta-analyses, letters, and short communications.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
